Testing of a Functional Outcome Measure for Those With Visual Field Defects (FOM)

This study has suspended participant recruitment.
(Lack of funding)
Sponsor:
Information provided by:
NovaVision, Inc.
ClinicalTrials.gov Identifier:
NCT00731796
First received: August 7, 2008
Last updated: March 5, 2011
Last verified: March 2011
  Purpose

This study is designed in two Phases. In phase 1, the Functional Outcome Measure will be tested to determine its validity and reliability in three populations, subjects that have not had a stroke and have no visual field defect, subjects that have had a stroke but do not have a visual field defect, and lastly subjects that have had a stroke and have a visual field defect. The second phase will employ an amended version of the functional outcome measure to be administered to two groups of subjects. The first group of subjects will be those subjects diagnosed with a visual field defect from retrochiasmatic insults and they will perform vision restoration therapy. The second group with a similar diagnosis to the first but who do not undergo vision restoration therapy.


Condition Intervention
Hemianopsia, Homonymous
Device: Functional Outcome Measure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Testing of a Functional Outcome Measure for Those With Visual Field Defects

Further study details as provided by NovaVision, Inc.:

Primary Outcome Measures:
  • Determine the ability of a Functional Outcome Measure to distinguish visual impairment in those with retrochiasmatic insults and visual field defects compared to those without visual field defects [ Time Frame: 18 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Identify the correlation between the degree of functional impairment and the amount of visual field loss [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Determine the ability of a Functional Outcome Measure to detect change after a rehabilitation intervention [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 190
Study Start Date: September 2007
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Stroke victims with a visual field deficit that undergo vision restoration therapy
Device: Functional Outcome Measure
Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
2
Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
Device: Functional Outcome Measure
Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
3
Stroke victims that do not have a visual field deficit
Device: Functional Outcome Measure
Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
4
Normal individuals who have not had a stroke and do not have a visual field deficit
Device: Functional Outcome Measure
Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.

Detailed Description:

The study will be conducted over 18 months and will be conducted in two phases:

Phase 1 In the first phase, we will determine the validity and reliability of Functional Outcome Measure by applying the Functional Outcome Measure to 20 subjects with homonymous visual field defects (VFD) due to a stoke, 20 stroke cases without visual field defects and 20 normal individuals. They will be asked to perform the Functional Outcome Measure a second time within the following 1-2 weeks in order to evaluate test-retest reliability. The expectation is that those without VFD (stroke and normal individuals) will have good or excellent results on the Functional Outcome Measure, while those with VFD will have abnormal results, thus reflecting the ability of this instrument to record the impairment present in those with VFD. In addition, it is anticipated that the results will be similar after retesting, ensuring test-retest reliability. An interim analysis will determine if the instrument is valid and if all its components correlate with the magnitude of visual field loss (as measured by High Resolution perimetry). Once the validation of the instrument has been accomplished, the functional outcome measure will be amended as suggested by this analysis to include only the items that correlate well with VFD.

The functional outcome measure will be administered either at the NovaVision, Inc. office (normal individuals) or in cooperating medical centers (stroke patients with or without visual field defect).

Phase 2 In the second phase, the amended version of the Functional Outcome Instrument will be administered to individuals with VFD. Two groups will be studied: 100 cases which will perform Vision Restoration Therapy (VRT), and 50 controls that will not. The latter group will include the 20 patients with VFD studied in Phase 1. Both groups will undergo visual field testing with high resolution perimetry, and will complete the Functional Outcome Measure on 4 occasions: twice within a 2 week interval at baseline, once after three months, and once after 6-7 months, with one of the groups having completed therapy during this time.

Visual field testing (high resolution perimetry) will be administered at cooperating medical centers. While patients undergoing VRT will perform the functional outcome measure once at the center and once on their VRT device at home, controls will perform their functional outcome measure at the medical center only, as they don't have access to a VRT device at home.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Normal participants who have not suffered a stroke and do not have a visual field deficit. Individuals who have suffered a stroke and do not have a visual field deficit. Individuals who have suffered a stroke and do have a visual field deficit.

Criteria

Inclusion Criteria:

  • Stroke victim
  • Read / Speak English (required to respond to the questionaire)
  • Ability to provide consent
  • Homonymous visual field defect evident on a suprathreshold visual field test (High Resolution Perimetry)
  • 18 years fo age and older

Exclusion Criteria:

  • Contraindication to visual stimulation: history of photogenic seizures
  • Inability to complete Vision Restoration Therapy
  • Significant cognitive impairment
  • Complete blindness or the inability to focus on a fixation point
  • Severe physical or behavioral limitations
  • Aphasia
  • Onset of Visual field defect less than 3 months prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731796

Locations
United States, Florida
NovaVision, Inc.
Boca Raton, Florida, United States, 33431
University of Miami Bascom Palmer
Miami, Florida, United States, 33136
United States, Georgia
Emory University School of Medicine Atlanta VA Medical Center Research
Atlanta, Georgia, United States, 30332
Sponsors and Collaborators
NovaVision, Inc.
Investigators
Principal Investigator: Sigrid Kenkel NovaVision, Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: Holger Weis, CFO, NovaVision, Inc.
ClinicalTrials.gov Identifier: NCT00731796     History of Changes
Other Study ID Numbers: NUSRPFOM01
Study First Received: August 7, 2008
Last Updated: March 5, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by NovaVision, Inc.:
Stroke
Retrochiasmatic
Vision
VFD

Additional relevant MeSH terms:
Scotoma
Hemianopsia
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases
Signs and Symptoms
Blindness

ClinicalTrials.gov processed this record on September 18, 2014